Krilogy Financial LLC Purchases Shares of 1,881 HCA Healthcare, Inc. $HCA

Krilogy Financial LLC purchased a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,881 shares of the company’s stock, valued at approximately $890,000.

Several other hedge funds and other institutional investors have also modified their holdings of HCA. Clearstead Trust LLC lifted its holdings in HCA Healthcare by 311.8% during the 2nd quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock worth $27,000 after purchasing an additional 53 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of HCA Healthcare by 82.9% in the third quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock valued at $32,000 after buying an additional 34 shares during the period. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of HCA Healthcare during the 2nd quarter worth $40,000. Compound Global Advisors LLC acquired a new stake in HCA Healthcare during the third quarter worth about $44,000. Finally, True Wealth Design LLC raised its holdings in shares of HCA Healthcare by 179.5% during the 3rd quarter. True Wealth Design LLC now owns 109 shares of the company’s stock worth $47,000 after buying an additional 70 shares in the last quarter. Institutional investors own 62.73% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. The Goldman Sachs Group increased their price objective on shares of HCA Healthcare from $520.00 to $558.00 and gave the company a “buy” rating in a research note on Wednesday, January 28th. Weiss Ratings reissued a “buy (b)” rating on shares of HCA Healthcare in a research note on Monday, December 29th. TD Cowen reaffirmed a “buy” rating on shares of HCA Healthcare in a research note on Wednesday, January 28th. Mizuho set a $540.00 target price on HCA Healthcare in a report on Monday, February 2nd. Finally, Argus upped their target price on HCA Healthcare from $530.00 to $560.00 and gave the company a “buy” rating in a report on Friday, February 6th. Sixteen research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $523.27.

Insiders Place Their Bets

In other HCA Healthcare news, SVP Jennifer Berres sold 8,020 shares of HCA Healthcare stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $514.58, for a total transaction of $4,126,931.60. Following the completion of the transaction, the senior vice president owned 11,993 shares of the company’s stock, valued at $6,171,357.94. The trade was a 40.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael S. Cuffe sold 1,500 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $498.09, for a total value of $747,135.00. Following the completion of the sale, the executive vice president owned 30,003 shares in the company, valued at $14,944,194.27. This trade represents a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,520 shares of company stock worth $6,894,067 in the last quarter. 1.30% of the stock is owned by company insiders.

HCA Healthcare News Summary

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA’s share performance is strong on a year‑over‑year basis (shares up ~75% YoY), reinforcing momentum and investor confidence in the company’s results and outlook. Read More.
• Positive Sentiment: Zacks and other analysts highlight earnings growth and price strength; Zacks added HCA to focus coverage and raised FY‑2026 EPS estimates, supporting forward earnings momentum and valuation. Read More.
• Positive Sentiment: HCA raised its quarterly dividend (new quarterly payout announced), which narrows yield risk and is a modest positive for income‑oriented investors. Read More.
• Positive Sentiment: Large institutional flows and stake increases (e.g., Norges Bank, Pacer, Viking Global) point to strong institutional demand and provide technical/supportive buying pressure for the stock. Read More.
• Neutral Sentiment: HCA completed a 43‑hospital EHR rollout and is tracking success metrics — operational execution that can improve efficiency and integration over time but has a gradual, not immediate, earnings impact. Read More.
• Neutral Sentiment: Local expansion moves — HCA Houston Healthcare Tomball acquired Supreme Care ER and StoneSprings plans a freestanding ER conversion — small, market‑level capacity adds that could modestly lift volumes in those geographies. Read More.
• Neutral Sentiment: HCA sold ASC real estate — a financing/portfolio move that could free capital or change lease terms; impact depends on transaction use of proceeds. Read More.
• Negative Sentiment: Insider selling: two senior VPs disclosed multi‑million dollar sales (Christopher Wyatt sold ~$2.0M; Jennifer Berres sold ~$4.13M). Significant insider sales can create short‑term selling pressure or raise governance/portfolio‑rebalancing questions. Read More. Read More.
• Negative Sentiment: Zacks/other outlets flagged a downward revision to HCA’s Q1 EPS forecast, which can pressure near‑term expectations even as FY estimates were raised. Read More.

HCA Healthcare Stock Up 0.9%

HCA stock opened at $539.91 on Friday. The firm has a market cap of $120.73 billion, a PE ratio of 19.02, a P/E/G ratio of 1.64 and a beta of 1.36. HCA Healthcare, Inc. has a 12-month low of $295.00 and a 12-month high of $552.90. The business has a 50 day moving average of $482.80 and a 200-day moving average of $448.23.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, beating the consensus estimate of $7.37 by $0.64. The business had revenue of $19.51 billion for the quarter, compared to the consensus estimate of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.HCA Healthcare’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.22 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, research analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 17th will be given a $0.78 dividend. This represents a $3.12 annualized dividend and a dividend yield of 0.6%. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.99%.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.